SOURCE: Crown Marketing

February 07, 2013 08:00 ET

Crown Marketing Reviews Positive In Vivo Testing

CHAPEL HILL, NC--(Marketwire - Feb 7, 2013) - Crown Marketing (OTCQB: CWNM) is pleased to announce that it has begun to review positive in vivo test results by examining blood plasma levels in test subjects using Crown's Controlled Drug Delivery Technology (CDDT). 

A clinical trial was conducted using 300 mg of Dexibuprofren Lysine and found that the blood plasma levels tracked the in vitro test results conducted earlier. The clinical trial appears to validate our belief and claims that because of the controllable diffusion dynamics and our mathematical modeling, we can predict with a high degree of certainty the release kinetics.

About The Company:

Crown's Controlled Drug Delivery Technology (CDDT) is a novel controlled-release technology, harnessing the principles of diffusion through precise mathematical formulas.

The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chronotherapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels. 

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.

More information can be found at: www.crowncddt.com

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information

  • Contact:

    Charles Van Der Ross
    347-491-0565